Physician profile
Ira Kumar
NPI 1528026432
$1,428.38
in general payments reported to CMS, 2019-2025
21 companies · $299 in 2025
The $299 reported for 2025 was more than what 85% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2021: $321 · 2022: $207 · 2023: $151 · 2024: $328 · 2025: $299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $778.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $778.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $217.43 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $206.58 | 2019-2024 | Gardasil 9, Vaxneuvance, Vaxelis |
| Pfizer INC. | $139.34 | 2019-2025 | |
| Inari Medical, INC. | $122.16 | 2021 | |
| Cranial Technologies, INC | $99.12 | 2023-2025 | Doc Band |
| Neurelis, INC. | $94.11 | 2025 | Valtoco |
| Ultragenyx Pharmaceutical INC. | $94.02 | 2021-2024 | Crysvita |
| Kyowa Kirin, INC. | $73.76 | 2024-2025 | Crysvita |
| Phadia US INC. | $56.16 | 2019-2023 | Immunocap |
| Kaleo, INC. | $48.42 | 2021-2022 | |
| Biomarin Pharmaceutical INC. | $46.54 | 2025 | Voxzogo 1.2mg |
| Corium, LLC | $40.62 | 2021-2022 | |
| Ars Pharmaceuticals Operations, INC. | $28.59 | 2025 | Neffy |
| Ironshore Pharmaceuticals INC. | $23.82 | 2019 | |
| Glaxosmithkline, LLC. | $23.65 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $22.28 | 2021 | |
| Sobi, INC | $22.03 | 2021 | |
| Mylan Pharmaceuticals INC. | $20.83 | 2019 | |
| Abbvie INC. | $18.90 | 2025 | |
| Cumberland Pharmaceuticals, INC. | $16.79 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.23 | 2024 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ira Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.